[Pharmacological and clinical study of the liquid drug form of nonachlazine].
A 1.5% nonachlazin solution containing substances which promote its absorption from the gastrointestinal tract increases coronary blood flow in cats 2--3 minutes after its administration into the stomach. After single administration this solution arrests a developing attack of angina pectoris in patients, improves the findings of spiroergometry, and in regular (3 times daily) medication prevents attacks of angina pectoris or makes them occurs less frequently in the very first 24 hours. The solution is most effective in patients with a high or moderate coronary reserve and affection of one or, in a lesser degree, of two coronary arteries. The solution does not cause a drop in arterial pressure, headache or dizziness.
D000328:Adult; D000368:Aged; D000818:Animals; D001783:Blood Flow Velocity; D002415:Cats; D002908:Chronic Disease; D003326:Coronary Circulation / Q000187:drug effects; D003327:Coronary Disease / Q000188:drug therapy; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D004562:Electrocardiography; D005080:Exercise Test; D006801:Humans; D008297:Male; D008875:Middle Aged; D009628:Nonachlazine / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D010640:Phenothiazines / Q000008:administration & dosage*
D010640:Phenothiazines; D009628:Nonachlazine
Farmakologicheskoe i klinicheskoe issledovanie zhidkoĭ lekarstvennoĭ formy nonakhlazina.